MS Speaks

Multiple Sclerosis => TREATMENTS => OCREVUS (ocrelizumab) => Topic started by: agate on September 17, 2019, 09:44:00 pm

Title: (ECTRIMS) Early Ocrevus use in PPMS slows disability risk, including risk of wheelchair reliance
Post by: agate on September 17, 2019, 09:44:00 pm
Hmm. No sooner has an announcement touting Mayzent (siponimod) as helpful in delaying the need for a wheelchair for persons with SPMS than it turns out that Ocrevus (ocrelizumab) can also help to keep the dreaded wheelchair away--though the claim here is for PPMS. From Multiple Sclerosis New Today (September 17, 2019)--"ECTRIMS 2019:  Early Ocrevus Use in PPMS Slows Risk of Disability, Including Risk of Wheelchair Reliance."


https://multiplesclerosisnewstoday.com/news-posts/2019/09/06/ectrims2019-early-ocrevus-use-slows-disability-ppms-including-wheelchair-dependence/



Title: Re: (ECTRIMS) Genentech reports Ocrevus living up to expectations
Post by: agate on September 19, 2019, 07:44:56 pm
A more comprehensive overview of some of the Ocrevus material presented at the ECTRIMS conference--again, from Multiple Sclerosis News Today (September 19). The spokespeople are drug company representatives.  There have been 7 PML cases so far, according to the article, but they are careful to point out these were all "carryover cases":


http://bit.ly/2kmpBr4